Semaglutide Patent
Sep 21, 2026
The Semaglutide Patent Cliff: A New Challenge for Novo Nordisk and Eli Lilly
Summary Semaglutide patent expiry is staggered, not simultaneous: early wave in 2026 (India, China, Brazil, Canada, South Africa), mid wave ~2031 (UK, EU4, Japan), late wave 2032–33 (US). India and China are the biggest near-term battlegrounds, covering ~40% of the world population and a third of global obes...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
